Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin

Trial Profile

A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2018

At a glance

  • Drugs Everolimus (Primary) ; Ribociclib (Primary)
  • Indications Duodenal cancer; Gastric cancer; Malignant thymoma; Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Dec 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.
    • 19 Dec 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
    • 27 Feb 2018 Last checked against Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top